The metastatic potential of patients following breast cancer neoadjuvant therapy is highly variable. Here, the authors demonstrated the predictive and prognostic value of ctDNA in 723 patients with high-risk early-stage breast cancer using serial analysis.
- Mark Jesus M. Magbanua
- Nayelis A. Manon
- Laura van ‘t Veer